Results 21 to 30 of about 269,737 (365)

FK506 IN PEDIATRIC KIDNEY-TRANSPLANTATION - PRIMARY AND RESCUE EXPERIENCE [PDF]

open access: yes, 1995
Between December 14, 1989, and December 17, 1993,43 patients undergoing kidney transplantation alone at the Children’s Hospital of Pittsburgh received FK506 as the primary immunosuppressive agent. The mean recipient age was 10.2 ± 4.8 years (range 0.7–17.
ELLIS, D   +13 more
core   +1 more source

Medical Complications of Lung Transplantation

open access: yesJournal of Chest Surgery, 2022
Lung transplantation (LT) is now considered as an effective treatment option for end-stage lung diseases that improves the short and long-term survival rates and quality of life.
Moo Suk Park
doaj   +1 more source

Transplant Coordinators' Perceived Impact of Availability of Multiple Generic Immunosuppression Therapies on Patients, Workload, and Posttransplant Maintenance Therapy

open access: yesJournal of Transplantation, 2013
Background. No studies have evaluated the impact of multiple generic immunosuppression medications on transplant coordinators (TCs) and patients. Methods.
K. Parker   +3 more
doaj   +1 more source

Fulminant Myocarditis in Patients With Autoimmune Disease That Requires Extracorporeal Membrane Oxygenation Support [PDF]

open access: yesTexas Heart Institute Journal
Myocarditis is a potentially life-threatening inflammatory disease of the myocardium, often resulting from infectious and immune-mediated responses. Clinical presentation in severe cases often results in a devastating illness requiring extracorporeal ...
Filip Depta, MD, PhD   +5 more
doaj   +1 more source

FIRST EXPERIENCE OF APPLICATION OF ASSIST CIRCULATION DEVICE USING BIVENTRICULAR TYPE «EXCOR»

open access: yesВестник хирургии имени И.И. Грекова, 2018
The frequency of use of assist blood device as the «bridge» to the heart transplantation increased in last years. An assessment of results of first 7 implantations of assist circulation device using biventricular type «Excor» was made.
M. L. Gordeev   +12 more
doaj   +1 more source

Changes in glucose metabolism among recipients with diabetes 1 year after kidney transplant: a multicenter 1-year prospective study

open access: yesFrontiers in Endocrinology, 2023
BackgroundDiabetes mellitus is a common and crucial metabolic complication in kidney transplantation. It is necessary to analyze the course of glucose metabolism in patients who already have diabetes after receiving a transplant.
Jun Bae Bang   +14 more
doaj   +1 more source

Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12 [PDF]

open access: yes, 2011
Immunotherapy-based strategies for gastrointestinal carcinomas (GIC) have been exploited so far, but these approaches have to face strong mechanisms of immune escape induced by tumours.
Alaniz   +69 more
core   +1 more source

A prospective randomized trial of FK506-based immunosuppression after renal transplantation [PDF]

open access: yes, 1995
A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/pred-nisone with FK506/azathioprine/prednisone after renal transplantation between August 1, 1991 and October 11,1992.
Demetris, AJ   +12 more
core   +1 more source

Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients

open access: yesFrontiers in Immunology, 2022
Repeated vaccination against SARS-CoV-2 increases serological response in kidney transplant recipients (KTR) with high interindividual variability. No decision support tool exists to predict SARS-CoV-2 vaccination response to third or fourth vaccination ...
Bilgin Osmanodja   +17 more
doaj   +1 more source

Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?

open access: yesFrontiers in Immunology, 2022
BackgroundExploring the cancer risks of rheumatoid arthritis (RA) patients with disease-modifying anti-rheumatic drugs (DMARDs) can help detect, evaluate, and treat malignancies at an early stage for these patients.
Yuzhuo Zhang   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy